查詢結果分析
相關文獻
- 表皮生長因子接受器於頭頸癌的角色及臨床治療之運用
- 頭頸癌
- 二氧化碳雷射鼓膜造孔術治療成人積液性中耳炎
- Heparin-Binding Epidermal Growth Factor-Like Growth Factor and Transforming Growth Factor-α in Human Non-Small Cell Lung Cancers
- 晚期頭頸癌患者安寧療護之挑戰--「高仁愛紀念病房」經驗
- 頭頸癌的國際疾病分類歸碼
- 臺灣地區頭頸癌概況
- 晚期頭頸癌之每天多次放射線治療
- A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer
- 國內常見癌症之早期診斷座談會
頁籤選單縮合
題 名 | 表皮生長因子接受器於頭頸癌的角色及臨床治療之運用=The Role of EGFR in Head and Neck Cancer and Treatment Implication |
---|---|
作 者 | 趙玉環; 王銘志; | 書刊名 | 光田醫學雜誌 |
卷 期 | 4:8 2009.09[民98.09] |
頁 次 | 頁53-60 |
分類號 | 418.31 |
關鍵詞 | 表皮生長因子接受器; 頭頸癌; Cetuximab; EGFR; Head and neck cancer; |
語 文 | 中文(Chinese) |
中文摘要 | 二十多年來局部侵襲性頭頸癌治療的典範為多科整合治療之模式,分子生物醫學的發展針對特定促進腫瘤生長及存活的分子標靶治療為最具前瞻性的治療策略。表皮生長因子接受器(EGFR)為ErbB家族的一員,EGFR與它的內源性配體接合後可以活化細胞內酪氨酸激酶進而調控細胞週期的進展。多數鱗狀細胞頭頸部癌症之腫瘤細胞其表皮生長因子接受器呈過度表現,表皮生長因子過度表現也意味著較差的預後和治療的阻抗性。Cetuximab為一IgG1單株抗體,可以抑制配體與表皮生長因子接受器接合進而抑制細胞增殖,促進細胞凋亡,降低血管新生阻止腫瘤細胞侵襲和轉移。本文將介紹表皮生長因子接受器在頭頸部癌症的角色和治療的運用。 |
英文摘要 | Over the past two decades the treatment paradigm for locally advanced head and neck cancer has been combined multidisciplinary approaches. A new generation of promising target therapies have been produced to target specific molecular processes that promote tumor growth and survival. Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. Its stimulation by endogenous ligands results in activation of intracellular tyrosine kinase, therefore, cell cycle progression. Head and neck cancer cells often express the epidermal growth factor receptor and its presence is associated with a poor prognosis and resistance to radiation. Cetuximab is an IgG1 monoclonal antibody that inhibits ligand binding to the EGFR inhibition of cell proliferation, enhanced apoptosis, reduced angiogenesis, invasiveness and metastases. In this article, we will introduce the role of EGFR in head and neck cancer and treatment implication. |
本系統中英文摘要資訊取自各篇刊載內容。